Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Barrier Therapeutics, Inc.
TrialMaster selected as EDC solution for seborrheic dermatitis trials
July 30th, 2003
OmniComm Systems, Inc., (OMCM), a developer of Internet-based technology solutions that streamline the process of collecting, validating, and managing clinical trial data, announced that Barrier Therapeutics, Inc., has selected OmniComm's TrialMaster as its product of choice. Barrier will use TrialMaster in their Seboride clinical trial for the treatment of seborrheic dermatitis. This trial will take place in the U.S. and in Europe involving 40 clinical research sites and 840 subjects. "We have closely followed the evolution of the TrialMaster product over the last few years, and are confident that this latest EDC product of OmniComm will enhance...
Source: Biotech Week (2003-07-30)
|
